Jasbir Seehra - 08 Apr 2023 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Chief Executive Officer, Director
Signature
/s/ Keith Regnante, Attorney-in-Fact
Issuer symbol
KROS
Transactions as of
08 Apr 2023
Transactions value $
$1,920
Form type
4
Filing time
11 Apr 2023, 16:05:25 UTC
Previous filing
17 Feb 2023
Next filing
15 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Options Exercise $1.92K +4K +1.61% $0.48* 253K 08 Apr 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -4K -8.15% $0.00 45.1K 08 Apr 2023 Common Stock 4K $0.48 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Fully vested and exercisable.